Pinned straw:
@jcmleng excellent write-up. And I agree this was a really good result on all metrics.
Good to see growing property numbers, growing ARPU, low churn, flattish CAC, and rapidly growing transaction revenues. It is also good to see management sticking to the vision of a "0.3%GBV to 1.5%GBV" opportunity, i.e., a 5X revenue growth opporutnity within the existing customer base.
It is particularly encouraging to see revenue growth trending back in the direction of the CEO's +30% goal, as transaction revenues kick in.
Given the "SaaSacre", the SP response is unsurprising. Afterall, how long until Claude issues its "Revenue and Channel Management Agent"? The presentation goes to some trouble to spell out the moat, for which a big part is the global dataset of room-nights and related relationships that $SDR can train its models on, as well as the ovided cost of making errors.
The only chart I would add is the 1H Cash Flow trend chart for the last 5 periods - albeit note that if you plot 1H and 2H the trend is less straighforward and not as compelling.

My definition of FCF is different from that used by management. I calculate OpCF + InvCF (excl. movements in cash/deposits) - Lease Repayments.
Management have a slightly more flattering free cash flow result than I think is correct (lease repayments are a real cash outflow, afterall).
But, that aside, the overall business direction of travel is clear in that this year, overall, should be cash generative.
Valuation
Yesterday, $SDR SP sunk to a very low level (<$3) compared with my valuation, which was $8.10 at a P/E in 2030 of 55. If we accept (as I think we must) that for the foreeable future at least, terminal values for SaaS businesses are fundamentally reset downwards, even if I was to say that the prospects of $SDR have changed so that the P/E in 2030 will only be 30, then that yields a valuation on my assumptions of $4.41.
So, it was tempting to add more yesterday. But to do so would be either to exhaust my remaining limited "dry powder" or sell the likes of $TNE, $PME, etc, which I also won't do. I am also not increasing my overall SaaS exposure by selling my biotech/pharma/medtech or industrials. So I am just content to do nothing.
Disc: Held (in RL 4.5%)